Avalo Therapeutics Downgraded by RBC to Sector Perform From Outperform, Price Target Cut to $0.75 From $9, Speculative Risk Kept
Avalo Therapeutics Downgraded by RBC to Sector Perform From Outperform, Price Target Cut to $0.75 From $9, Speculative Risk Kept
加拿大皇家银行将Avalo Therapeutics的评级从跑赢大盘下调至板块表现,目标股价从9美元下调至0.75美元,投机风险保持不变
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册